1,192 results on '"Kobbe, Guido"'
Search Results
52. Supplement 5 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
53. Supplement 6 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
54. Supplement 1 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
55. Supplement 2 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
56. Supplement 7 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
57. Supplement 3 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
58. Supplement 8 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
59. Supplement 4 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
60. Myelodysplastic syndromes: new methods of diagnosis, prognostication, and treatment
61. Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS
62. EASIX for prediction of survival in lower-risk myelodysplastic syndromes
63. Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia
64. Double-Blind, Randomized, Placebo-Controlled Multi-Center Phase III Study Followed by Open-Label Phase on the Efficacy and Tolerability of Budesonide in Patients with Resistant Oral Chronic GVHD: Part 2 – Pain, Subjective Measures and Safety Analysis
65. Double-Blind, Randomized, Placebo-Controlled Multi-Center Phase III Study Followed By Open-Label Phase on the Efficacy and Tolerability of Budesonide in Patients with Resistant Oral Chronic GVHD: Part 1 - Efficacy Analysis
66. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy
67. Change of prognosis of patients with myelodysplastic syndromes during the last 30 years
68. Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
69. Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component
70. Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
71. Wearable based monitoring and self-supervised contrastive learning detect clinical complications during treatment of Hematologic malignancies
72. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
73. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation
74. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation
75. A retrospective study evaluating the impact of infectious complications during azacitidine treatment
76. Blood Stem Cell Mobilization in Solid Tumors: Experience with Plerixafor and Alternative Ways of Hematopoietic Stem Cell Mobilization
77. High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma
78. Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT
79. Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
80. The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation
81. Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
82. Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study
83. Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis
84. Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience.
85. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
86. Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma
87. Total body irradiation + fludarabine compared to busulfan + fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT
88. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT.
89. Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
90. Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
91. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
92. Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis
93. The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation
94. Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation:a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT
95. Multiple myeloma–related deregulation of bone marrow–derived CD34+ hematopoietic stem and progenitor cells
96. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
97. Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
98. Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-Based High-Dose Sequential Conditioning Regimen
99. The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter
100. Outcomes of anti‐programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real‐world analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.